Altimmune, Inc. (ALT) shares surged 6.69% in after-hours trading on Tuesday, following positive topline results from Merck's Phase 3 MK-3475A-D77 trial evaluating the subcutaneous administration of pembrolizumab (Keytruda) together with Altimmune's berahyaluronidase alfa (ALT-B4) in combination with chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC).
The trial met its dual primary pharmacokinetic endpoints, demonstrating non-inferior exposure of the subcutaneous pembrolizumab formulation compared to intravenous Keytruda when administered with chemotherapy. Secondary endpoints of efficacy and safety were generally consistent between the two treatment arms.
These positive results suggest that the subcutaneous pembrolizumab formulation, if approved, could improve the treatment experience for patients by reducing administration time and increasing access compared to intravenous infusion. Merck plans to discuss the data with regulatory authorities worldwide as soon as possible.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。